{"id":758349,"date":"2023-05-11T21:08:55","date_gmt":"2023-05-12T01:08:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/"},"modified":"2023-05-11T21:08:55","modified_gmt":"2023-05-12T01:08:55","slug":"immunitybio-kaplan-fox-investigates-immunitybio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/","title":{"rendered":"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, May  11, 2023  (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YYbbNxJ0BjLohhVbEDnzhzBVPXeGy0hZSpvwgozPpPybjOxmd9bUuMuwdkDtiP5iTzbA9YXL7q2hGoRrQC9l4Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.kaplanfox.com<\/u><\/a>) is investigating claims on behalf of investors of ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ: IBRX). <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5h7NdpLdl4x8hYxrJhkaBQgd7N4d6gCtM4dsE4lM3cUdd8Fmuir0Kqx5UIHbAyVNjBA6gFcclSuTbGw3mhizHxFqaYT6kl6_OTMCB3ekFUA0kTxoOo0bAX5uSOeLM_eN72yx0Ez46A1t-mCz5XM6Dg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Click Here to Join Investigation.<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>If you acquired ImmunityBio common stock and would like to discuss our investigation, please <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yEtMgPIEzA3RHBbvbHlih5JmamgLiVlU7wVKuure1QKtZ6hhygZq3tpjozUBL6bXJ3r8k2AP3en1sBNtgVu3hmtIegzYyzCsuC050P8aOApZ-JKdMqhP9D6EWt9yUNKY\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>click here<\/u><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong> or contact us by emailing <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=86B_mv7y6kUZpe-JLEovFX9dc1TVubd7mJJUwYPdA1dSnZtGDGZcc-jFziioKWXvc-IFETu8T8BGOkrqvfpOMN3f7GQo_SgkHQdEdgOMIg0=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>pmayer@kaplanfox.com<\/u><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong> or by calling (646) 315-9003. <\/strong>\n      <\/p>\n<p align=\"justify\">On May 11, 2023, ImmunityBio disclosed in a filing with the Securities and Exchange Commission that the Company \u201chas received a complete response letter from the U.S. Food and Drug Administration (\u201cFDA\u201d) on May 9, 2023 regarding its Biologics License Application (\u201cBLA\u201d) for its product candidate, Anktiva (N-803) in combination with Bacillus Calmette-Gu\u00e9rin (\u201cBCG\u201d) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (\u201cNMIBC\u201d) with carcinoma in situ (\u201cCIS\u201d) with or without Ta or T1 disease.\u201d The letter indicates that the FDA has determined that it cannot approve the BLA in its present form based on \u201cdeficiencies relate[d] to the FDA\u2019s pre-license inspection of the Company\u2019s third-party contract manufacturing organizations\u201d and that \u201c[s]atisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved.\u201d<\/p>\n<p align=\"justify\">In midday trading on May 11, 2023, ImmunityBio shares fell over 54%.<\/p>\n<p align=\"justify\">\n        <strong>WHY CONTACT KAPLAN FOX &#8211; <\/strong>Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox &amp; Kilsheimer LLP, you may visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YYbbNxJ0BjLohhVbEDnzh9-1hUhuqauxMRERMDeF83W0w3i6Po3ua65CmaonJNLwIAbjcwdAjHTPLoNkE42nlw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.kaplanfox.com<\/u><\/a>.<\/p>\n<p align=\"justify\">If you have any questions about this investigation, please contact:<\/p>\n<p align=\"justify\">Pamela A. Mayer <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 800 Third Avenue, 38th Floor <br \/> New York, New York\u00a010022 <br \/> (646) 315-9003 <br \/> E-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=86B_mv7y6kUZpe-JLEovFQPDvkhjEKor_HYE-a6pxw76bgmx9unwzaA1qVNLsaS5JUayH5ShyB-kkaApgZ50Xd3Kgw5_zu1FHeEDmJC-2xI=\" rel=\"nofollow noopener\" target=\"_blank\"><u>pmayer@kaplanfox.com<\/u><\/a><\/p>\n<p align=\"start\">Laurence D. King <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 1999 Harrison Street, Suite 1560 <br \/> Oakland, California 94612 <br \/> (415) 772-4704 <br \/> Fax: (415) 772-4707 <br \/> E-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G5oIwvPePrcWm1ijXiSU0Vbin3llCLo-7eVmux7RqdvPJyvt1EZc2-d5rIO3P31BToMRFjMSdzlHM-xKQ6xhm7OeFvS0wmCfRJweMpjtNPA=\" rel=\"nofollow noopener\" target=\"_blank\"><u>lking@kaplanfox.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/N2UzODY1NDYtNTI5OC00MzIxLTgxM2YtMDFhOTgyMjJhNjQ0LTEwMzE5OTk=\/tiny\/Kaplan-Fox-Kilsheimer-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ: IBRX). Click Here to Join Investigation. If you acquired ImmunityBio common stock and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On May 11, 2023, ImmunityBio disclosed in a filing with the Securities and Exchange Commission that the Company \u201chas received a complete response letter from the U.S. Food and Drug Administration (\u201cFDA\u201d) on May 9, 2023 regarding its Biologics License Application (\u201cBLA\u201d) for its product candidate, Anktiva (N-803) in combination with Bacillus Calmette-Gu\u00e9rin (\u201cBCG\u201d) for the treatment of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758349","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ: IBRX). Click Here to Join Investigation. If you acquired ImmunityBio common stock and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On May 11, 2023, ImmunityBio disclosed in a filing with the Securities and Exchange Commission that the Company \u201chas received a complete response letter from the U.S. Food and Drug Administration (\u201cFDA\u201d) on May 9, 2023 regarding its Biologics License Application (\u201cBLA\u201d) for its product candidate, Anktiva (N-803) in combination with Bacillus Calmette-Gu\u00e9rin (\u201cBCG\u201d) for the treatment of &hellip; Continue reading &quot;IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-12T01:08:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio\",\"datePublished\":\"2023-05-12T01:08:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/\"},\"wordCount\":355,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/\",\"name\":\"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=\",\"datePublished\":\"2023-05-12T01:08:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-kaplan-fox-investigates-immunitybio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/","og_locale":"en_US","og_type":"article","og_title":"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio - Market Newsdesk","og_description":"NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ: IBRX). Click Here to Join Investigation. If you acquired ImmunityBio common stock and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On May 11, 2023, ImmunityBio disclosed in a filing with the Securities and Exchange Commission that the Company \u201chas received a complete response letter from the U.S. Food and Drug Administration (\u201cFDA\u201d) on May 9, 2023 regarding its Biologics License Application (\u201cBLA\u201d) for its product candidate, Anktiva (N-803) in combination with Bacillus Calmette-Gu\u00e9rin (\u201cBCG\u201d) for the treatment of &hellip; Continue reading \"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-12T01:08:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio","datePublished":"2023-05-12T01:08:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/"},"wordCount":355,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/","name":"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=","datePublished":"2023-05-12T01:08:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODAwMCM1NTkxNTk3IzIwMjA4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-kaplan-fox-investigates-immunitybio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758349"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}